Last reviewed · How we verify
Brivaracetam infusion
Brivaracetam binds to synaptic vesicle protein 2A (SV2A) to reduce neuronal excitability and prevent seizures.
Brivaracetam binds to synaptic vesicle protein 2A (SV2A) to reduce neuronal excitability and prevent seizures. Used for Adjunctive treatment of partial-onset seizures in patients with epilepsy, Adjunctive treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy.
At a glance
| Generic name | Brivaracetam infusion |
|---|---|
| Sponsor | UCB Pharma |
| Drug class | Antiepileptic agent (SV2A ligand) |
| Target | SV2A (synaptic vesicle protein 2A) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Brivaracetam is a high-affinity ligand for SV2A, a synaptic vesicle glycoprotein involved in neurotransmitter release. By binding to SV2A, it modulates synaptic transmission and reduces the propensity for seizure activity. This mechanism is similar to levetiracetam but with higher selectivity and potency for SV2A.
Approved indications
- Adjunctive treatment of partial-onset seizures in patients with epilepsy
- Adjunctive treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy
Common side effects
- Somnolence
- Fatigue
- Dizziness
- Headache
- Irritability
- Nausea
Key clinical trials
- Comparison of Intravenous Brivaracetam Versus Levetiracetam in the Management of Status Epilepticus (NA)
- A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures (PHASE3)
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy (PHASE2)
- A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting (PHASE2)
- Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint (PHASE2, PHASE3)
- A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects (PHASE1)
- Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy (PHASE3)
- Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |